Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)

Market Cap	43.83B +32.3%
Revenue (ttm)	5.17B +45.4%
Net Income	2.18B +52.6%
EPS	4.85 +52.5%
Shares Out	450.00M
PE Ratio	20.08
Forward PE	19.07
Dividend	0.80 (0.83%)
Ex-Dividend Date	n/a

Volume	4,652,928
Average Volume	4,414,908
Open	96.97
Previous Close	95.97
Day's Range	94.55 - 97.73
52-Week Range	80.53 - 122.20
Beta	0.27
RSI	53.22
Earnings Date	Apr 23, 2026

About SHA:688578

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China. Its lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), as well as for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 1,823
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688578

Financial Performance

In 2025, SHA:688578's revenue was 5.17 billion, an increase of 45.36% compared to the previous year's 3.56 billion. Earnings were 2.18 billion, an increase of 52.55%.